Meeting
2023 ASCO Annual Meeting
Relationship between tumor microenvironment (TME)-based histomic TGFβ signature (TGFBs), stromal fibroblast recruitment, and exclusion of immune cells as immunotherapy resistance mechanisms.
Authors
Gahee Park
Lunit Inc., Seoul, South Korea
Gahee Park , Jongchan Park , Jeanne Shen , Yoon-La Choi , Taebum Lee , Hyojin Kim , Young Kwang Chae , Se-Hoon Lee , Sehhoon Park , Jin-haeng Chung , Chiyoon Oum , Minuk Ma , Melody SeungHui Seo , Chan-Young Ock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2585)
DOI
10.1200/JCO.2023.41.16_suppl.2585
Abstract #
2585
Poster Bd #
427
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Artificial intelligence (AI)-powered immune phenotyping to predict outcomes of immuno-oncology (IO)-based regimens in hepatocellular carcinoma (HCC).
First Author: Hongjae Chon
Poster
2023 ASCO Annual Meeting
Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC).
First Author: Hyunwook Kim
Poster
2023 ASCO Annual Meeting
Artificial intelligence (AI) –powered spatial analysis of macrophages in tumor microenvironment and its association with interferon-gamma (IFNG) signature and immune phenotype (IP) in pan-cancer dataset.
First Author: Chiyoon Oum
Poster
2018 ASCO Annual Meeting
Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.
First Author: Ameen Abdulla Salahudeen